CoChat
Sign Up
Cited by 32Bone Metabolism and DiseasesBone health and osteoporosis researchThyroid Disorders and Treatments

Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation

Open access
Deng, Tuo, Zhang, Wenwen, Zhang, Yanling, Zhang, Mengqi, Huan, Zhikun, Yu, Chunxiao, Zhang, Xiujuan, Wang, Yan +1 more·2021·BMC Endocrine Disorders
DOI 10.1186/s12902-021-00715-8PMC PMC7968288

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Background: As the incidence of secretory osteoporosis has increased, bone loss, osteoporosis and their relationships with thyroid-stimulating hormone (TSH) have received increased attention. In this study, the role of TSH in bone metabolism and its possible underlying mechanisms were investigated. Methods: We analyzed the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and TSH and the bone mineral density (BMD) levels of 114 men with normal thyroid function. In addition, osteoblasts from rat calvarial samples were treated with different doses of TSH for different lengths of time. The related gene and protein expression levels were investigated. Results: A comparison of the BMD between the high-level and low-level serum TSH groups showed that the TSH serum concentration was positively correlated with BMD. TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control ( P < 0.05, P < 0.01). Bone morphogenetic protein (BMP)2 activity was enhanced with both increased TSH concentration and increased time. The protein levels of Runx2 and osterix were increased in a dose-dependent manner. Conclusions: The circulating concentrations of TSH and BMD were positively correlated with normal thyroid function in males. TSH promoted osteoblast proliferation and differentiation in rat primary osteoblasts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12902-021-00715-8

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. [1]Martin T Gooi JH Molecular mechanisms in coupling of bone formation to resorption Crit Rev Eukaryot Gene Expr 2009 19 73 88 10.1615/CritRevEukarGeneExpr.v19.i1.40 19191758 · DOI
  2. [2]Matsuo K Osteoclast-osteoblast communication Arch Biochem Biophys 2008 473 201 209 10.1016/j.abb.2008.03.027 18406338 · DOI · Paper page
  3. [3]Phan TC Xu J Interaction between osteoblast and osteoclast: impact in bone disease Histol Histopathol 2004 19 1325 1344 15375775
  4. [4]Zhang W Zhang Y Liu Y Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation J Biomech 2014 47 1307 1314 10.1016/j.jbiomech.2014.02.015 24629929 · DOI
  5. [5]Bassett JH Williams GR Role of thyroid hormones in skeletal development and bone maintenance Endocr Rev 2016 37 135 187 10.1210/er.2015-1106 26862888 PMC4823381 · DOI · Paper page
  6. [7]Biondi B Cooper DS Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer Thyroid. 2010 20 2 135 146 10.1089/thy.2009.0311 20151821 · DOI · Paper page
  7. [9]Xu N Wang Y Xu Y Effect of subclinical hyperthyroidism on osteoporosis: a meta-analysis of cohort studies Endocrine. 2020 69 1 39 48 10.1007/s12020-020-02259-8 32207036 · DOI
  8. [10]Faber J Galløe AM Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis Eur J Endocrinol 1994 130 4 350 356 10.1530/eje.0.1300350 8162163 · DOI · Paper page
  9. [11]Kung AW Yeung SS Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin J Clin Endocrinol Metab 1996 81 3 1232 1236 10.1210/jcem.81.3.8772604 8772604 · DOI
  10. [12]Müller CG Bayley TA Harrison JE Tsang R Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance Thyroid. 1995 5 2 81 87 10.1089/thy.1995.5.81 7647577 · DOI
  11. [13]Guo CY Weetman AP Eastell R Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine Clin Endocrinol 1997 46 3 301 307 10.1046/j.1365-2265.1997.1280950.x 9156039 · DOI
  12. [14]Mendonça Monteiro de Barros G Madeira M Vieira Neto L Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients J Bone Miner Metab 2016 34 4 417 421 10.1007/s00774-015-0680-4 26056020 · DOI · Paper page
  13. [15]Wojcicka A Bassett JH Williams GR Mechanisms of action of thyroid hormones in the skeleton Biochim Biophys Acta 2012 1830 3979 3986 10.1016/j.bbagen.2012.05.005 22634735 · DOI
  14. [16]Bassett JH van der Spek A Logan JG Thyrostimulin regulates Osteoblastic bone formation during early skeletal development Endocrinology 2015 156 3098 3113 10.1210/en.2014-1943 26018249 PMC4541616 · DOI
  15. [17]Abe E Marians RC Yu W TSH is a negative regulator of skeletal remodeling Cell 2003 115 151 162 10.1016/S0092-8674(03)00771-2 14567913 · DOI · Paper page
  16. [18]Bassett JH Williams AJ Murphy E A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism Mol Endocrinol 2008 22 501 512 10.1210/me.2007-0221 17932107 PMC2234586 · DOI
  17. [19]Sampath TK Simic P Sendak R Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats J Bone Miner Res 2007 22 849 859 10.1359/jbmr.070302 17352644 · DOI
  18. [20]Hase H Ando T Eldeiry L TNFalpha mediates the skeletal effects of thyroid-stimulating hormone Proc Natl Acad Sci U S A 2006 103 12849 12854 10.1073/pnas.0600427103 16908863 PMC1568936 · DOI
  19. [21]Gogakos AI Duncan Bassett JH Thyroid and bone Arch Biochem Biophys 2010 503 129 136 10.1016/j.abb.2010.06.021 20599658 · DOI
  20. [22]Baliram R Latif R Berkowitz J Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures Proc Natl Acad Sci U S A 2011 108 16277 16282 10.1073/pnas.1110286108 21911383 PMC3182731 · DOI
  21. [23]Tsai JA, Janson A, Bucht E, Kindmark H, Marcus C, Stark A, Rawet Zemack H, Torring O. Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcif Tissue Int. 2004;74(5):486–91. 10.1007/s00223-003-0108-3. 14961213 · DOI
  22. [24]Wang J Zhang W Yu C Zhang X Zhang H Guan Q Zhao J Xu J Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation PLoS One 2015 10 8 e0134986 10.1371/journal.pone.0134986 26241313 PMC4524683 · DOI
  23. [25]Gogakos A Logan JG Waung JA THRA and DIO2 mutations are unlikely to be a common cause of increased bone mineral density in euthyroid post-menopausal women Eur J Endocrinol 2014 170 637 644 10.1530/EJE-13-1009 24480136 · DOI
  24. [26]Allain TJ Thyroid hormones and bone J Endocrinol 1993 139 9 18 10.1677/joe.0.1390009 8254298 · DOI
  25. [27]Lee WY Oh KW Rhee EJ Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women Arch Med Res 2006 37 511 516 10.1016/j.arcmed.2005.09.009 16624651 · DOI
  26. [29]Ding B Zhang Y Li Q Low thyroid stimulating hormone levels are associated with low bone mineral density in femoral neck in elderly women Arch Med Res 2016 47 310 314 10.1016/j.arcmed.2016.07.009 27664492 · DOI
  27. [31]Svare A Nilsen TI Bjøro T Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study Eur J Endocrinol 2009 161 779 786 10.1530/EJE-09-0139 19671706 · DOI
  28. [32]Kim MK Yun KJ Kim MH The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma Bone 2015 71 101 105 10.1016/j.bone.2014.10.009 25445448 · DOI
  29. [33]Leader A Ayzenfeld RH Lishner M Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years J Clin Endocrinol Metab 2014 99 2665 2673 10.1210/jc.2013-2474 24885627 · DOI
  30. [35]Siderova M Hristozov K TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves’ disease and Graves’ orbitopathy Arch Endocrinol Metab 2018 62 221 226 10.20945/2359-3997000000027 29768627 PMC10118993 · DOI
  31. [36]Jeon EJ Lee KY Choi NS Bone morphogenetic protein-2 stimulates Runx2 acetylation J Biol Chem 2006 281 16502 16511 10.1074/jbc.M512494200 16613856 · DOI
  32. [37]Matsubara T Kida K Yamaguchi A BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation J Biol Chem 2008 283 29119 29125 10.1074/jbc.M801774200 18703512 PMC2662012 · DOI
  33. [38]Sivertsen B Holliday N Madsen AN Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor Br J Pharmacol 2013 170 1349 1362 10.1111/bph.12361 24032557 PMC3838681 · DOI
  34. [39]Boutin A Neumann S Multiple Transduction Pathways Mediate Thyrotropin Receptor signaling in Preosteoblast-Like Cells Endocrinology 2016 157 2173 2181 10.1210/en.2015-2040 26950201 PMC4870888 · DOI
  35. [40]Davies TF Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies Expert Opin Ther Targets 2015 19 835 847 10.1517/14728222.2015.1018181 25768836 PMC4484771 · DOI
  36. [41]Baliram R Latif R Zaidi M Expanding the role of thyroid-stimulating hormone in skeletal physiology Front Endocrinol (Lausanne) 2017 8 252 10.3389/fendo.2017.00252 29042858 PMC5632520 · DOI
  37. [42]Baliram R Chow A Huber AK Thyroid and bone: macrophage-derived TSH-β splice variant increases murine osteoblastogenesis Endocrinology 2013 154 4919 4926 10.1210/en.2012-2234 24140716 PMC3836071 · DOI
  38. [43]Baliram R Latif R Morshed SA T3 regulates a human macrophage-derived TSH-β splice variant: implications for human bone biology Endocrinology 2016 157 3658 3667 10.1210/en.2015-1974 27300765 PMC5007892 · DOI
  39. [44]Vincent BH Montufar-Solis D Teng BB Bone marrow cells produce a novel TSHbeta splice variant that is upregulated in the thyroid following systemic virus infection Genes Immun 2009 10 18 26 10.1038/gene.2008.69 18754015 PMC2629504 · DOI
  40. [45]Latif R Ali MR Ma R New small molecule agonists to the thyrotropin receptor Thyroid 2015 25 51 62 10.1089/thy.2014.0119 25333622 PMC4291085 · DOI
  41. [46]Boutin A Eliseeva E Gershengorn MC β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation FASEB J 2014 28 3446 3455 10.1096/fj.14-251124 24723693 PMC4101659 · DOI
  42. [47]Neumann S Huang W Titus S Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice Proc Natl Acad Sci U S A 2009 106 12471 12476 10.1073/pnas.0904506106 19592511 PMC2708975 · DOI
  43. [48]Latif R Realubit RB Karan C TSH receptor signaling abrogation by a novel small molecule Front Endocrinol (Lausanne) 2016 7 130 10.3389/fendo.2016.00130 27729899 PMC5037132 · DOI

Cited by

Sorted by citations

Authors
Deng, T., Zhang, W., Zhang, Y., Zhang, M., Huan, Z., Yu, C., Zhang, X., Wang, Y., & Xu, J.
Affiliations
Shandong University (CN)
Corresponding author
Xu, Jin
ORCID
Venue
BMC Endocrine Disorders
Publisher
Springer Science and Business Media LLC
Published
2021-03-16
Volume
21
Issue
1
Pages
49-49
ISSN
1472-6823 (ISSN-L)
DOI
10.1186/s12902-021-00715-8
PMC
PMC7968288
OpenAlex
W3137335283
Cited by
32
References
5
Citations by year
2026: 4 · 2025: 10 · 2024: 8 · 2023: 3 · 2022: 6 · 2021: 1
FWCI
1.41
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Key Technology Research and Development Program of Shandong (2017G006006, 2016GGH3118)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
thyroid-stimulating hormone, osteoporosis, bone mineral density, osteoblast proliferation, osteogenic differentiation, bone metabolism, Runx2, Osterix, BMP-2, calvarial osteoblasts, thyroid function
MeSH terms
Adult, Animals, Animals, Newborn, Cell Differentiation, Cells, Cultured, China, Cross-Sectional Studies, Humans, Male, Middle Aged, Osteoblasts, Osteoporosis, Risk Factors, Thyrotropin, Thyroxine, Triiodothyronine, Bone Density, Cell Proliferation, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review